Literature DB >> 27650058

An Application of NGS for Molecular Investigations in Perrault Syndrome: Study of 14 Families and Review of the Literature.

Justine Lerat1, Laurence Jonard2, Natalie Loundon3, Sophie Christin-Maitre4, Didier Lacombe5, Cyril Goizet5, Cécile Rouzier6, Lionel Van Maldergem7, Souad Gherbi8, Eréa-Nöel Garabedian3, Jean-Paul Bonnefont2, Philippe Touraine9, Isabelle Mosnier10, Arnold Munnich11, Françoise Denoyelle3, Sandrine Marlin8.   

Abstract

Perrault syndrome (PS) is a rare autosomal recessive condition characterized by deafness and gonadic dysgenesis. Recently, mutations in five genes have been identified: C10orf2, CLPP, HARS2, HSD17B4, and LARS2. Probands included are presented with sensorineural deafness associated with gonadic dysgenesis. DNA was sequenced using next-generation sequencing (NGS) with a panel of 35 deafness genes including the five Perrault genes. Exonic variations known as pathogenic mutations or detected with <1% frequency in public databases were extracted and subjected to segregation analysis within each family. Both mutations and low coverage regions were analyzed by Sanger sequencing. Fourteen female index patients were included. The screening in four cases has been extended to four family members presenting with PS phenotype. For four unrelated patients (28.6%), causative mutations were identified: three homozygous mutations in C10orf2, CLPP, and HARS2, and one compound heterozygous mutation in LARS2. Three additional heterozygous mutations in LARS2 and HSD17B4 were found in three independent familial cases. All these missense mutations were verified by Sanger sequencing. Familial segregation analyses confirmed the molecular diagnosis in all cases carrying biallelic mutations. Because of NGS, molecular analysis confirmed the clinical diagnosis of PS in 28.6% of our cohort and four novel mutations were found in four Perrault genes. For the unsolved cases, exome sequencing should be performed to search for a sixth unknown PS gene.
© 2016 WILEY PERIODICALS, INC.

Entities:  

Keywords:  C10orf2; CLPP; HARS2; HSD17B4; LARS2; NGS; Perrault syndrome

Mesh:

Substances:

Year:  2016        PMID: 27650058     DOI: 10.1002/humu.23120

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  18 in total

1.  Performance comparison: exome sequencing as a single test replacing Sanger sequencing.

Authors:  Hila Fridman; Concetta Bormans; Moshe Einhorn; Daniel Au; Arjan Bormans; Yuval Porat; Luisa Fernanda Sanchez; Brent Manning; Ephrat Levy-Lahad; Doron M Behar
Journal:  Mol Genet Genomics       Date:  2021-03-11       Impact factor: 3.291

Review 2.  Deafness and Vestibulopathy in Cerebellar Diseases: a Practical Approach.

Authors:  Orlando G Barsottini; José Luiz Pedroso; Carlos Roberto Martins; Marcondes Cavalcante França; Pedro Mangabeira Albernaz
Journal:  Cerebellum       Date:  2019-12       Impact factor: 3.847

Review 3.  Mitochondrial Dysfunction in Primary Ovarian Insufficiency.

Authors:  Dov Tiosano; Jason A Mears; David A Buchner
Journal:  Endocrinology       Date:  2019-10-01       Impact factor: 4.736

Review 4.  When a common biological role does not imply common disease outcomes: Disparate pathology linked to human mitochondrial aminoacyl-tRNA synthetases.

Authors:  Ligia Elena González-Serrano; Joseph W Chihade; Marie Sissler
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

5.  Next Generation Sequencing Should Be Proposed to Every Woman With "Idiopathic" Primary Ovarian Insufficiency.

Authors:  Sarah Eskenazi; Anne Bachelot; Justine Hugon-Rodin; Genevieve Plu-Bureau; Anne Gompel; Sophie Catteau-Jonard; Denise Molina-Gomes; Didier Dewailly; Catherine Dodé; Sophie Christin-Maitre; Philippe Touraine
Journal:  J Endocr Soc       Date:  2021-03-01

6.  Biallelic variants in LARS2 and KARS cause deafness and (ovario)leukodystrophy.

Authors:  Marjo S van der Knaap; Marianna Bugiani; Marisa I Mendes; Lisa G Riley; Desiree E C Smith; Joëlle Rudinger-Thirion; Magali Frugier; Marjolein Breur; Joanna Crawford; Judith van Gaalen; Meyke Schouten; Marjolaine Willems; Quinten Waisfisz; Frederic Tran Mau-Them; Richard J Rodenburg; Ryan J Taft; Boris Keren; John Christodoulou; Christel Depienne; Cas Simons; Gajja S Salomons; Fanny Mochel
Journal:  Neurology       Date:  2019-02-08       Impact factor: 11.800

7.  Specific MRI Abnormalities Reveal Severe Perrault Syndrome due to CLPP Defects.

Authors:  Tom E J Theunissen; Radek Szklarczyk; Mike Gerards; Debby M E I Hellebrekers; Elvira N M Mulder-Den Hartog; Jo Vanoevelen; Rick Kamps; Bart de Koning; S Lane Rutledge; Thomas Schmitt-Mechelke; Carola G M van Berkel; Marjo S van der Knaap; Irenaeus F M de Coo; Hubert J M Smeets
Journal:  Front Neurol       Date:  2016-11-16       Impact factor: 4.003

8.  Novel neuro-audiological findings and further evidence for TWNK involvement in Perrault syndrome.

Authors:  Monika Ołdak; Dominika Oziębło; Agnieszka Pollak; Iwona Stępniak; Michal Lazniewski; Urszula Lechowicz; Krzysztof Kochanek; Mariusz Furmanek; Grażyna Tacikowska; Dariusz Plewczynski; Tomasz Wolak; Rafał Płoski; Henryk Skarżyński
Journal:  J Transl Med       Date:  2017-02-08       Impact factor: 5.531

9.  LARS2-Perrault syndrome: a new case report and literature review.

Authors:  Maria Teresa Carminho-Rodrigues; Phillipe Klee; Sacha Laurent; Michel Guipponi; Marc Abramowicz; Hélène Cao-van; Nils Guinand; Ariane Paoloni-Giacobino
Journal:  BMC Med Genet       Date:  2020-05-18       Impact factor: 2.103

10.  Perrault syndrome type 3 caused by diverse molecular defects in CLPP.

Authors:  Erica J Brodie; Hanmiao Zhan; Tamanna Saiyed; Kaye N Truscott; David A Dougan
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.